ArticleNeoplasia (New York, N.Y.)2022
Spatiotemporal trends of the global burden of melanoma in 204 countries and territories from 1990 to 2019: Results from the 2019 global burden of disease study.
Article in Neoplasia (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Regional Variations in Melanoma Histologic Characteristics: A Multicenter Cohort Study from Two Southeastern European Countries.Journal of clinical medicine · 2026Article
- Clinicopathologic gene expression profiling in lieu of sentinel lymph node biopsy: A case report in an uninsured patient with melanoma.JAAD case reports · 2026Article
- Burdens of Malignant Melanoma and Projections for 2050 in Asia: Findings from the 2023 Global Burden of Disease Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Omics in Cutaneous Melanoma.Asian Pacific journal of cancer prevention : APJCP · 2025Review
- 18F-FDG PET/CT Impact on Malignant Melanoma Patients Undergoing Staging and Restaging: A Single-University-Center Experience in a Real-World Setting.Diagnostics (Basel, Switzerland) · 2025Article
- A Consolidated Review of Contemporary Targeted and Immunotherapeutic Options for Melanoma.Biomedicines · 2025Review
- Patterns and trends in melanoma mortality in Spain (1999-2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Socioeconomic status correlates with clinical outcomes in patients with acral melanoma.Frontiers in public health · 2025Article
- Who visits primary health care general practitioners and why? A register-based study in a Finnish city.International journal of circumpolar health · 2024Article
- Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials.Cells · 2024Review
- The Potential of Circulating miR-193b, miR-146b-3p and miR-483-3p as Noninvasive Biomarkers in Cutaneous Melanoma Patients.Molecular biotechnology · 2024Article
- Trauma plays an important role in acral melanoma: A retrospective study of 303 patients.Cancer medicine · 2024Article
- Article
- Molecular Imaging of Melanoma VEGF-expressing Tumors through [Anti-cancer agents in medicinal chemistry · 2024Article
- CXCL10 promotes melanoma angiogenesis and tumor growth.Animal cells and systems · 2024Article
- A signature of seven hypoxia-related lncRNAs is a potential biomarker for predicting the prognosis of melanoma.American journal of cancer research · 2024Article
- The effects of exposure to solar radiation on human health.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2023Article
- Enhancing Skin Cancer Immunotheranostics and Precision Medicine through Functionalized Nanomodulators and Nanosensors: Recent Development and Prospects.International journal of molecular sciences · 2023Review
- Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma.Journal of translational medicine · 2023Article
- Trends in the Burden of COPD Attributable to Ambient PMRisk management and healthcare policy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to estimate the latest magnitudes and temporal trends of melanoma burden at the national, regional, and global levels. The data on melanoma incidence, deaths, and disability-adjusted life-years (DALYs) in 204 countries and territories between 1990 and 2019 came from the Global Burden of Disease 2019 Study. Estimated annual percentage change (EAPC) was calculated to depict the temporal trends and Spearman rank correlation was used to analyze the influential factors of EAPC. From 1990 to 2019, the incident cases of melanoma increased by 170% to 289,950, death increased by 90% to 62,840, and DALYs increased by 67% to 1,707,800 globally. The age-standardized incidence rate (ASIR) of melanoma increased globally by an average of 1.13 [95% confidence interval (CI): 0.93-1.32], while the age-standardized rates of death and DALYs both declined with the EAPC of -0.27 (95% CI: -0.36 to -0.19) and -0.49 (95% CI: -0.57 to -0.41). In 2019, the highest burden of melanoma was observed in Australasia, followed by high-income North America and Europe regions, which all presented an incremental growth in ASIR. The positive association between the EAPC in ASIR and socio-demographic index (SDI) in 2019 (ρ = 0.600, P < 0.001) suggested that countries with higher SDI have experienced a more rapid increase in ASIR of melanoma. In conclusion, the burden of melanoma is increasing globally but differed greatly across the world. Notably, the high burden areas are facing a continuing increase in incidence, which implies more targeted strategies should be taken for reducing the increasing melanoma burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.